T ¼¼Æ÷ Ä¡·á ½ÃÀå : Ä¡·á¹ý, Ä¡·á À¯Çü, ÀûÀÀÁõº° - ¼¼°è ¿¹Ãø(2025-2030³â)
T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication - Global Forecast 2025-2030
»óǰÄÚµå : 1597834
¸®¼­Ä¡»ç : 360iResearch Private Limited
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 184 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,939 £Ü 5,699,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 4,249 £Ü 6,147,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿Àϱâ¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 5,759 £Ü 8,332,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ Áö¿ª »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 6,969 £Ü 10,083,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

T ¼¼Æ÷ Ä¡·á ½ÃÀåÀº 2023³â¿¡ 81¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 98¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 21.23%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 313¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

T¼¼Æ÷ Ä¡·á´Â ¸é¿ª Ä¡·áÀÇ Áß¿äÇÑ ÇÑ ºÐ¾ß·Î, À¯ÀüÀÚ º¯Çü T¼¼Æ÷¸¦ ÀÌ¿ëÇØ ¾Ï¼¼Æ÷¸¦ Ç¥ÀûÀ¸·Î »ï¾Æ ÆÄ±«ÇÏ´Â °ÍÀ¸·Î, Çö´ë ¾Ï Ä¡·á¿¡¼­ Å« ÀáÀç·ÂÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ±× Çʿ伺Àº ±âÁ¸ Ä¡·á¿¡ ¹ÝÀÀÇÏÁö ¾Ê´Â Á¾¾ç¿¡ ´ëóÇÒ ¼ö ÀÖ´Â ´É·Â¿¡ ÀÖÀ¸¸ç, ¸ÂÃã Ä¡·á ¿É¼ÇÀ» ¼³¸íÇÕ´Ï´Ù. ±× ¿ëµµ¿Í ÃÖÁ¾ ¿ëµµ´Â ¹éÇ÷º´, ¸²ÇÁÁ¾°ú °°Àº Ç÷¾×¾Ï¿¡¼­ °íÇü¾Ï¿¡ À̸£±â±îÁö º´¿ø, ¿¬±¸±â°ü, »ý¸í°øÇÐ ±â¾÷¿¡ À̸£±â±îÁö ´Ù¾çÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº CAR-T ¹× TCR Ä¡·áÀÇ ¹ßÀü, »ý¸í°øÇп¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ¾Ï ¹ßº´·ü Áõ°¡ µîÀÔ´Ï´Ù. ±×·¯³ª »ý»ê ºñ¿ë, º¹ÀâÇÑ ±ÔÁ¦ »óȲ, ÀáÀçÀû ºÎÀÛ¿ëÀº ¼ºÀåÀ» ÀúÇØÇÏ´Â ÁÖ¿ä Á¦ÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÃÖ±ÙÀÇ ºñÁî´Ï½º ±âȸ´Â T ¼¼Æ÷ÀÇ È¿´ÉÀ» Çâ»ó½ÃŰ´Â CRISPR°ú °°Àº À¯ÀüÀÚ ÆíÁý ±â¼úÀÇ ¹ßÀü°ú ÀÚ°¡¸é¿ªÁúȯ°ú °°Àº ºñÁ¾¾çÇÐÀûÀÎ ÀÀ¿ë ºÐ¾ß·ÎÀÇ È®´ë·Î ÀÎÇØ »ý°Ü³ª°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇϱâ À§Çؼ­´Â Á¦Á¶ °øÁ¤ÀÇ °£¼ÒÈ­¿Í ºñ¿ë Àý°¨À» À§ÇØ »ý¸í°øÇÐ ±â¾÷°ú Çа谡 Çù·ÂÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÕ´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î º¤ÅÍ ½Ã½ºÅÛ ¹× Àü´Þ ¹æ¹ýÀ» ÅëÇØ ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» °³¼±ÇÏ´Â µ¥ ÁýÁßÇÔÀ¸·Î½á ±ÔÁ¦Àû °úÁ¦¿Í »çȸÀû ¿ì·Á¿¡ ´ëÀÀÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àü¸Á¿¡µµ ºÒ±¸Çϰí, ½ÃÀåÀº ³ôÀº Ä¡·á ºñ¿ë, ³Ãµ¿ º¸°üµÈ ¼¼Æ÷ ¼ö¼ÛÀÇ ¹°·ù, ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇϱâ À§ÇÑ ´ë±Ô¸ð ÀÓ»ó½ÃÇèÀÇ Çʿ伺 µîÀÇ Àå¾Ö¹°¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ±â¼ú Çõ½ÅÀº »ý»ê ½Ã°£°ú ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ´Â µ¿Á¾ T¼¼Æ÷ÀÇ °³¹ß, Ç¥Àû ½Äº° Á¤È®¼ºÀ» ³ôÀ̰í Á¤¹ÐÀǷḦ º¸ÀåÇÏ´Â Â÷¼¼´ë ½ÃÄö½Ì ±â¹ýÀÇ È°¿ë°ú °°Àº ºÎ¹®¿¡¼­ Ȱ¹ßÇÏ°Ô ÀÌ·ç¾îÁú ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚ ¼±Åðú Ä¡·á¹ý ¸ÂÃãÈ­¿¡ ÀΰøÁö´ÉÀ» Ȱ¿ëÇÏ¿© ÃÖÀûÈ­µÈ Ä¡·á °á°ú¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ±â¼ú ¹ßÀüÀÌ ºü¸£°Ô ÁøÇàµÊ¿¡ µû¶ó ½ÃÀå ¿ªÇÐÀº ¸Å¿ì ¿ªµ¿ÀûÀ̱⠶§¹®¿¡ ÀÌÇØ°ü°èÀÚµéÀÌ °æÀï¿¡¼­ »ì¾Æ³²±â À§Çؼ­´Â ÁøÈ­ÇÏ´Â ¿¬±¸ °³¹ßÀÇ ÃÖÀü¼±¿¡ ¹ÎøÇÏ°Ô ´ëÀÀÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 81¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 98¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 313¾ï ´Þ·¯
CAGR(%) 21.23%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â T ¼¼Æ÷ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®À» °ø°³ÇÕ´Ï´Ù.

T¼¼Æ÷Ä¡·áÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Porter's Five Forces: T¼¼Æ÷Ä¡·áÁ¦ ½ÃÀå °ø·«À» À§ÇÑ Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â µ¥ Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀïÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ¸ð»öÇϱâ À§ÇÑ ¸íÈ®ÇÑ ¹æ¹ýÀ» ¼³¸íÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» º¸¿ÏÇϰí, ÀáÀçÀû µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : T¼¼Æ÷Ä¡·áÁ¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

PESTLE ºÐ¼® : T¼¼Æ÷Ä¡·áÁ¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº T¼¼Æ÷ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ ´ã°í ÀÖÀ¸¸ç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀ̰í Àû±ØÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : T¼¼Æ÷Ä¡·áÁ¦ ½ÃÀå °æÀï»óȲ ÆÄ¾Ç

T¼¼Æ÷Ä¡·áÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ¼¼ºÐÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, À̸¦ ÅëÇØ °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º: T¼¼Æ÷Ä¡·áÁ¦ ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â T¼¼Æ÷Ä¡·áÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ: T ¼¼Æ÷ Ä¡·á ½ÃÀå¿¡¼­ ¼º°øÀÇ ±æÀ» ±×¸³´Ï´Ù.

T¼¼Æ÷Ä¡·áÁ¦ ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» ´Þ¼ºÇÒ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÎ¹®¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ±â¼úÇϰí ÀÖ½À´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, »ê¾÷ÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ, ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The T-Cell Therapy Market was valued at USD 8.13 billion in 2023, expected to reach USD 9.85 billion in 2024, and is projected to grow at a CAGR of 21.23%, to USD 31.30 billion by 2030.

T-cell therapy, a pivotal facet of immunotherapy, utilizes genetically modified T-cells to target and destroy cancer cells, presenting significant potential in modern oncology treatments. Its necessity lies in its ability to address tumors unresponsive to conventional therapies, offering personalized treatment options. The application and end-use scope range from blood cancers, such as leukemia and lymphoma, to solid tumors, spanning hospitals, research institutes, and biotech companies. Market growth is predominantly driven by advancements in CAR-T and TCR therapies, increased investment in biotechnology, and rising cancer prevalence. However, production cost, complex regulatory landscapes, and potential side effects serve as notable limitations hindering growth. The latest opportunities arise from advances in gene editing technologies like CRISPR, which could enhance T-cell efficacy, and expansion into non-oncological applications, such as autoimmune diseases. To capitalize on these opportunities, collaboration between biotech firms and academic institutions to streamline manufacturing processes and mitigate costs is recommended. Moreover, focusing on improving safety profiles through novel vector systems and delivery methods can address regulatory challenges and public concerns. Despite these prospects, the market faces hurdles in terms of high therapy costs, logistics of cryopreserved cell transport, and the need for extensive clinical trials to ensure safety and efficacy. Innovation can thrive in areas like developing allogeneic T-cells, which could reduce manufacturing time and cost, and harnessing next-generation sequencing methods for better target identification, ensuring precision medicine. Additionally, tapping into artificial intelligence for patient selection and therapy customization can yield optimized outcomes. The nature of the market is highly dynamic, with rapid technological progress, making it crucial for stakeholders to remain agile and responsive to evolving research and development fronts to maintain a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 8.13 billion
Estimated Year [2024] USD 9.85 billion
Forecast Year [2030] USD 31.30 billion
CAGR (%) 21.23%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving T-Cell Therapy Market

The T-Cell Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Porter's Five Forces: A Strategic Tool for Navigating the T-Cell Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the T-Cell Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the T-Cell Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the T-Cell Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the T-Cell Therapy Market

A detailed market share analysis in the T-Cell Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the T-Cell Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the T-Cell Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the T-Cell Therapy Market

A strategic analysis of the T-Cell Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the T-Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Amgen Inc., Bluebird Bio, Inc., Bristol Myers Squibb, DiaCarta, Inc., Fate Therapeutics Inc., Gilead Sciences, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Poseida Therapeutics Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., and Tessa Therapeutics Pte. Ltd..

Market Segmentation & Coverage

This research report categorizes the T-Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. T-Cell Therapy Market, by Modality

7. T-Cell Therapy Market, by Therapy Type

8. T-Cell Therapy Market, by Indication

9. Americas T-Cell Therapy Market

10. Asia-Pacific T-Cell Therapy Market

11. Europe, Middle East & Africa T-Cell Therapy Market

12. Competitive Landscape

Companies Mentioned

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â